SCCA clinical trial breaks new ground, becomes FDA approved

April 7, 2017

On April 6, 2017, the SCCA published an article on the newly FDA approved treatment for Merkel cell carcinoma. “While skin cancer is one of the most common cancers, patients with a rare form called Merkel cell carcinoma have not had an approved treatment option until now,” said Dr. Richard Pazdur, acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research and director of the FDA’s Oncology Center of Excellence, in a statement.

To read more, click here to view the article.